HS-20089

HS-20089 is an antibody-drug conjugate developed by Hansoh BioMedical R&D. The sponsor describes its target as B7-H4, which OnCo does not yet have a target page for. The sponsor states: HS-20089 is a humanised IgG1 anti-B7-H4 monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a protease-cleavable linker (average drug-to-antibody ratio of about 6), delivering the payload to B7-H4-expressing tumour cells, given intravenously every three weeks in ovarian and endometrial cancer. ClinicalTrials.gov describes the intervention as: All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatmen. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06855069 (HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer), in ovarian cancer and endometrial cancer. The largest, NCT06855069, plans to enrol 468 participants with primary completion expected 2027-03-07. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.